A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer

• Published in: Oncology Vol. 69; no. 4; p. 333
• Main Authors: Kosmas, Christos, Tsavaris, Nicolas, Koutras, Aggelos, Makatsoris, Thomas, Mylonakis, Nicolas, Tzelepis, George, Dimitrakopoulos, Antonis, Spyropoulos, Konstantinos, Polyzos, Aristidis, Karabelis, Athanasios, Kalofonos, Haralambos P
• Format: Journal Article
• Language: English
• Published: Switzerland 01-01-2005
• Subjects: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - secondary; Drug Administration Schedule; Female; Humans; Ifosfamide - administration & dosage; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids - administration & dosage; Treatment Outcome
• ISSN: 0030-2414
• DOI: 10.1159/000089681

In the present phase II study we evaluated the docetaxel-ifosfamide-carboplatin (DICb) combination in the outpatient setting in patients with advanced non-small-cell lung cancer (NSCLC).
Patients with advanced NSCLC (stages IIIB/IV), WHO performance status (PS) <2, and no prior chemotherapy were eligible. Chemotherapy drug doses were: docetaxel: 80 mg/m2, ifosfamide: 3.5 g/m2, and carboplatin at a target area under the curve of 5 (based on Calvert's formula), all on day 1, followed by prophylactic G-CSF.
Fourty patients were entered and all are evaluable for response and toxicity: median age: 64 (48-72); PS: 1 (0-1); gender: 29 males/11 females; stages: IIIB: 13 (33%), IV: 27 (67%). Metastatic sites at diagnosis included: lymph nodes: 25; bone: 7; liver: 4; brain: 5; lung nodules: 13; adrenals: 6. Responses were as follows: 22/40 [55%; 95% confidence interval (CI), 54-81%] evaluable patients responded: 4 complete responses, 18 partial responses, 11 had stable disease, and 7 had progressive disease. The median response duration was 7 months (range 2-14 months), median time to progression 9 months (range 2-18 months) and median overall survival 11 months (range 3-46+ months). 1-year survival was 47.5%. Grade 3/4 toxicities included: neutropenia 28/40, with 12 developing grade 4 and 12% febrile neutropenia, thrombocytopenia grade 3: 3/40 and grade 4: 1/40, no grade 3 neuropathy, grade 1 CNS toxicity in 3, no renal toxicity, 8 grade 2 diarrhea and 4 grade 3 vomiting.
In the present phase II study the DICb combination yielded important activity and good tolerability in advanced NSCLC.